Journal
MOLECULAR CANCER THERAPEUTICS
Volume 18, Issue 7, Pages 1255-1264Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-18-0919
Keywords
-
Categories
Funding
- Italian Association for Cancer Research [MFAG14456]
Ask authors/readers for more resources
The DNA damage response (DDR) kinases ATR, Chk1, and Weel play vital roles in the response to replication stress and in maintaining cancer genomic stability. Inhibitors of these kinases are currently under clinical investigation. Mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) are aggressive lymphomas whose clinical outcome is still largely unsatisfactory. These cell lymphoma subtypes are highly dependent on both Chk1 and Weel for survival. We investigated the activity of the ATR inhibitor AZD6738 as single agent and in combination with either Chk1 (AZD6738) or Weel (AZD1775) inhibitors in several preclinical models of MCL and DLBCL. This study included predinical in vitro activity screening on a large panel of cell lines, both as single agent and in combination, and validation experiments on in vivo models. Cellular and molecular mechanisms of the observed synergistic effect as well as pharmacodynamic analysis of in vivo samples were studied. AZD6738 exerted a strong synergistic cytotoxic effect in combination with both AZD7762 and AZD1775 in the 2 lymphoma subtypes regardless of their TP53, MYC, and ATM mutational status. These DDR inhibitor combinations, similarly to the Chkl/Weel inhibitor combination, caused a marked S-phase delay, with an increase in cydin-dependent kinases (CDK) activity, increased DNA damage, and decreases in Weel, MYC, and RRM2 protein levels. The synergistic in vitro activity translated to striking in vivo antitumor activity. DDR-DDR inhibitor combinations could potentially offer promising novel therapeutic strategies for patients with B-cell lymphoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available